Research programme: small molecule drug discovery - Evotec AG/MGI GP
Latest Information Update: 19 Feb 2008
At a glance
- Originator Evotec AG; MGI GP
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma
- 09 Feb 2005 Preclinical trials in Undefined in Germany (unspecified route)